Brigatinib 30mg, 90mg, 180mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 30mg, 90mg, 180mg

Reference Brands: Alunbrig (USA)

Category: Oncology Cancer Care

Brigatinib is a tyrosine kinase inhibitor (TKI) used in the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). It works by blocking abnormal ALK protein activity that promotes cancer cell growth. Brigatinib is available as oral film-coated tablets in 30 mg, 90 mg, and 180 mg strengths. It is prescribed as a targeted therapy for patients who have progressed on or are intolerant to other ALK inhibitors like crizotinib.

Product Description:

Brigatinib is a next-generation ALK inhibitor with a distinctive breadth of activity against resistance mutations, including several that defeat crizotinib and some that defeat alectinib. It also inhibits ROS1, EGFR and other kinases. Like other second-generation agents it crosses into the central nervous system, where ALK-positive lung cancer frequently spreads.

It is used for ALK-positive non-small cell lung cancer, first-line and after crizotinib. Its characteristic problem is early pulmonary toxicity: a syndrome of dyspnoea, cough and hypoxia occurring within the first days of treatment in a small proportion of patients, which is why the drug is started at a lower dose for a week before escalation. Hypertension, raised creatine kinase, raised pancreatic enzymes and visual disturbance are common. It is a CYP3A4 substrate, so strong inhibitors and inducers require dose adjustment.

Sourcing notes. Originator product, on patent, no generic. ALK testing is a prerequisite. The mandatory lead-in dosing means the starting pack differs from the maintenance pack, and both must be supplied — a packaging detail that matters when quoting a course rather than a strength.